Literature DB >> 16722935

Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma.

J R Kneile1, G Tan, S Suster, P E Wakely.   

Abstract

AIMS: Undifferentiated nasopharyngeal non-keratinizing carcinoma (UNPC), formerly known as lymphoepithelioma, frequently metastasizes at an early stage to regional lymph nodes and, thus, may be difficult to distinguish from Hodgkin's lymphoma (HL) or anaplastic large cell lymphoma (ALCL). CD30 expression is a useful diagnostic stain in both HL and ALCL, but its expression in UNPC deserves clarification. The aim of this study was to evaluate CD30 expression in UNPC and lymphoepithelioma-like carcinoma (LELC) from other anatomic locations and compare it with ALCL and squamous cell carcinoma (SCC). METHODS AND
RESULTS: CD30 immunoreactivity was examined in 38 cases of primary or metastatic UNPC, six cases of LELC, 10 cases of SCC and seven cases of ALCL. CD30 immunoreactivity was observed in four of 38 (10.5%) cases of UNPC. CD30 staining was absent in all cases of LELC (0/6) and SCC (0/10). All cases of ALCL (7/7) were strongly positive for CD30.
CONCLUSIONS: The majority of cases of UNPC are immunohistochemically negative for CD30; however, a small subset of cases expresses CD30 antigen. These findings provide additional evidence that CD30 expression is not restricted to neoplasms of lymphoid origin. This should be taken into consideration when interpreting CD30 immunohistology and the possibility of UNPC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16722935     DOI: 10.1111/j.1365-2559.2006.02449.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

1.  Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.

Authors:  Lei Kang; Dawei Jiang; Emily B Ehlerding; Todd E Barnhart; Dalong Ni; Jonathan W Engle; Rongfu Wang; Peng Huang; Xiaojie Xu; Weibo Cai
Journal:  Mol Pharm       Date:  2018-03-20       Impact factor: 4.939

2.  CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases.

Authors:  Meghna Alimchandani; Zeng-Feng Wang; Markku Miettinen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014 May-Jun

Review 3.  Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

Authors:  Garrett K Berger; Ali McBride; Stephanie Lawson; Kelsey Royball; Seongseok Yun; Kevin Gee; Irbaz Bin Riaz; Ahlam A Saleh; Soham Puvvada; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2016-11-21       Impact factor: 6.312

4.  Lymphocyte deficiency limits Epstein-Barr virus latent membrane protein 1 induced chronic inflammation and carcinogenic pathology in vivo.

Authors:  Adele Hannigan; Asif M Qureshi; Colin Nixon; Penelope M Tsimbouri; Sarah Jones; Adrian W Philbey; Joanna B Wilson
Journal:  Mol Cancer       Date:  2011-02-03       Impact factor: 27.401

5.  Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.

Authors:  Bin Li; Steven A Eschrich; Anders Berglund; Melissa Mitchell; David Fenstermacher; Hadi Danaee; Hongyue Dai; Daniel Sullivan; William L Trepicchio; William S Dalton
Journal:  JMIR Res Protoc       Date:  2017-03-20

6.  System analysis of the regulation of the immune response by CD147 and FOXC1 in cancer cell lines.

Authors:  Yu-Kui Shang; Can Li; Ze-Kun Liu; Ling-Min Kong; Ding Wei; Jing Xu; Zi-Ling Wang; Huijie Bian; Zhi-Nan Chen
Journal:  Oncotarget       Date:  2018-01-11

7.  Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics.

Authors:  Samer Nassif; Ziad M El-Zaatari; Michel Attieh; Maya Hijazi; Najla Fakhreddin; Tarek Aridi; Fouad Boulos
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.